Frankfurt-listed drug discovery business Evotec will harness the power of its comprehensive drug discovery infrastructure and expertise, using assays, chemical starting points and x-ray crystallographic tools licensed from Harvard.
Germany-based Evotec is to collaborate with US-based Harvard University to discover and developing novel anti-bacterial agents in the hope of creating a new class of antibiotics. Frankfurt-listed drug discovery business Evotec will harness the power of its comprehensive drug discovery infrastructure and expertise, using assays, chemical starting points and x-ray crystallographic tools licensed from Harvard.…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
